Cargando...
ABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics
Dolutegravir (DTG) is a potent integrase inhibitor of human immunodeficiency virus. Because DTG is a substrate of the efflux transporter ABCG2 and ABCG2 is highly polymorphic, we asked whether dose adjustment of DTG is needed for ABCG2-deficient individuals. Using Abcg2-null mice, the current work i...
Guardado en:
| Publicado en: | J Pharmacol Exp Ther |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
The American Society for Pharmacology and Experimental Therapeutics
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7292963/ https://ncbi.nlm.nih.gov/pubmed/32303561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.119.264424 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|